N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype
暂无分享,去创建一个
S. Vowler | H. Grönberg | D. Neal | S. Menon | F. Wiklund | P. Wiklund | A. Warren | C. Massie | A. Ramos-Montoya | H. Whitaker | S. Menon | C. Massie | L. Egevad | J. Kay | A. Seipel | P. Wiklund | J. Kay | F. Wiklund | B. Thomas | L. L. Shiong | D. E. Neal | J. Miller | J. Miller | Amanda H. Seipel | D. Neal | Benjamin Thomas | Jodi Miller | Benjamin C. Thomas
[1] A. Rosato,et al. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. , 2013, European journal of cancer.
[2] William C. Eckelman,et al. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[3] H. Klocker,et al. Anterior gradient 2 and 3 – two prototype androgen‐responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells , 2013, The FEBS journal.
[4] D. Ruderman,et al. Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype , 2013, The Prostate.
[5] Shankar Vallabhajosula,et al. Prostate-specific membrane antigen-based imaging. , 2013, Urologic oncology.
[6] K. Pummer,et al. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness , 2013, The Prostate.
[7] S. Horvath,et al. Prostate cancer cell phenotypes based on AGR2 and CD10 expression , 2012, Modern Pathology.
[8] Jeonghoon Lee,et al. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. , 2012, Bioorganic & medicinal chemistry letters.
[9] W. Ellis,et al. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine , 2012, The Prostate.
[10] B. Ring,et al. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. , 2012, American journal of clinical pathology.
[11] Jian Wang,et al. Spondin-2 (SPON2), a More Prostate-Cancer-Specific Diagnostic Biomarker , 2012, PloS one.
[12] Robert Langer,et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.
[13] K. Korkmaz,et al. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells , 2012, Molecular and Cellular Endocrinology.
[14] Chris Metcalfe,et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.
[15] I. Mills,et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.
[16] Daniel R. Dries,et al. γ-Secretase-regulated Proteolysis of the Notch Receptor by Mitochondrial Intermediate Peptidase* , 2011, The Journal of Biological Chemistry.
[17] K. Korkmaz,et al. Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3β signaling, and its knockdown results in deregulated G2/M transition in prostate cells. , 2011, DNA and cell biology.
[18] B. Vojtesek,et al. Anterior gradient 2: a novel player in tumor cell biology. , 2011, Cancer letters.
[19] J. Edwards,et al. GRP78 up‐regulation is associated with androgen receptor status, Hsp70–Hsp90 client proteins and castrate‐resistant prostate cancer , 2011, The Journal of pathology.
[20] R. Eeles,et al. The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine , 2010, PloS one.
[21] K. Ryan,et al. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells , 2010, Cell Death and Disease.
[22] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[23] Hsiang-Cheng Chi,et al. Positive regulation of spondin 2 by thyroid hormone is associated with cell migration and invasion. , 2010, Endocrine-related cancer.
[24] J. Schalken,et al. The use of PCA3 in the diagnosis of prostate cancer , 2009, Nature Reviews Urology.
[25] I. Mills,et al. LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals , 2009, Clinical Cancer Research.
[26] H. Lilja,et al. Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer , 2009, Current opinion in urology.
[27] Anbupalam Thalamuthu,et al. A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki Disease , 2009, PLoS genetics.
[28] Mark J. Dunning,et al. BASH: a tool for managing BeadArray spatial artefacts , 2008, Bioinform..
[29] Xiang Li,et al. Overexpression of JKTBP1 induces androgen‐independent LNCaP cell proliferation through activation of epidermal growth factor‐receptor (EGF‐R) , 2008, Cell biochemistry and function.
[30] Zheng Wang,et al. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. , 2008, Cancer research.
[31] B. Zheng,et al. High expression of PSM‐E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate‐specific membrane antigen , 2007, The Prostate.
[32] S. Groshen,et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. , 2007, Human pathology.
[33] S. Tavaré,et al. beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..
[34] D. Neal,et al. Labeling and identification of LNCaP cell surface proteins: A pilot study , 2007, The Prostate.
[35] S. Gamble,et al. Mechanisms of androgen receptor repression in prostate cancer. , 2006, Biochemical Society transactions.
[36] J. Konvalinka,et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer , 2006, The EMBO journal.
[37] M. Conkright,et al. CREB: the unindicted cancer co-conspirator. , 2005, Trends in cell biology.
[38] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[39] P. Sharp,et al. Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Konvalinka,et al. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. , 2004, European journal of biochemistry.
[41] J. Konvalinka,et al. Identification of the N‐glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity , 2004, Protein science : a publication of the Protein Society.
[42] I. Krantz,et al. A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3 , 2004, Human Genetics.
[43] Camilo Rojas,et al. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. , 2002, Analytical biochemistry.
[44] S. Weed,et al. Focal Adhesion Kinase: a regulator of focal adhesion dynamics and cell movement , 2000, Oncogene.
[45] A. Woodard,et al. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. , 1999, Cancer research.
[46] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[47] T. Matsui,et al. Cloning and characterization of a cDNA encoding a novel heterogeneous nuclear ribonucleoprotein-like protein and its expression in myeloid leukemia cells. , 1998, Journal of biochemistry.
[48] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[49] J. Guan,et al. Phosphorylation of Tyrosine 397 in Focal Adhesion Kinase Is Required for Binding Phosphatidylinositol 3-Kinase* , 1996, The Journal of Biological Chemistry.
[50] Norbert Gretz,et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. , 2005, Anticancer research.
[51] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[52] A. Renshaw,et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] P. Walsh,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. , 1997, The Journal of urology.